The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease
Open accessAbstract
Diabetes increases the risk of liver disease progression and cirrhosis development in patients with nonalcoholic steatohepatitis (NASH). The association between diabetes and the risk of hepatocellular carcinoma (HCC) in NASH patients with cirrhosis is not well quantified. All patients with the diagnosis of NASH cirrhosis seen at Mayo Clinic Rochester between January 2006 and December 2015 were identified. All adult liver transplant registrants with NASH between 2004 and 2017 were identified using the United Network for Organ Sharing (UNOS)/Organ Procurement and Transplantation registry for external validation. Cox proportional hazard analysis was performed to investigate the association between diabetes and HCC risk. Among 354 Mayo Clinic patients with NASH cirrhosis, 253 (71%) had diabetes and 145 (41%) were male. Mean age at cirrhosis evaluation was 62. During a median follow-up of 47 months, 30 patients developed HCC. Diabetes was associated with an increased risk of developing HCC in univariate (hazard ratio [HR] = 3.6; 95% confidence interval [CI] = 1.1-11.9; P = 0.04) and multivariable analysis (HR = 4.2; 95% CI = 1.2-14.2; P = 0.02). In addition, age (per decade, HR = 1.8; 95% CI = 1.2-2.6; P < 0.01) and low serum albumin (HR = 2.1; 95% CI = 1.5-2.9; P < 0.01) were significantly associated with an increased risk of developing HCC in multivariable analysis. Other metabolic risk factors, including body mass index, hyperlipidemia, and hypertension, were not associated with HCC risk. Among UNOS NASH registrants (N = 6,630), 58% had diabetes. Diabetes was associated with an increased risk of developing HCC in univariate (HR = 1.4; 95% CI = 1.1-1.8; P < 0.01) and multivariable (HR = 1.3; 95% CI = 1.0-1.7; P = 0.03) analysis. Conclusion: Diabetes is associated with an increased risk of HCC in patients with NASH cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Another study reported a 4-fold increased risk of HCC in individuals with T2D and MASH-related cirrhosis followed for 47 months.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [55]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,135
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
Calle, E. E., & Kaaks, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1408 · Cited by 3,613
A central role for JNK in obesity and insulin resistance
Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., Karin, M., & Hotamisligil, G. S. (2002) · Nature · doi:10.1038/nature01137 · Cited by 3,359
Estes, C., Razavi, H. A., Loomba, R. S., Younossi, Z. M., & Sanyal, A. J. (2017) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,496
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Estes, C., Anstee, Q. M., Arias, M., Bantel, H., Bellentani, S., Caballería, J., Colombo, M., Craxì, A., Crespo, J., Day, C. P., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.036 · Cited by 2,046
Altekruse, S. F., McGlynn, K. A., & Reichman, M. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7753 · Cited by 1,695
Mann, C. J. (2003) · Emergency Medicine Journal · doi:10.1136/emj.20.1.54 · Cited by 1,558 · cited 1×
“potential temporal causal relationship between diabetes and HCC among NASH cirrhosis patients.(38)”
Background
Flagged first, then by citations
Cited by
Sorted by citations
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
Global Epidemiology and Genetics of Hepatocellular Carcinoma
Toh, M. R., Wong, E. Y. T., Wong, S. H., Ng, A. W. T., Loo, L., Chow, P. K.-H., & Ngeow, J. Y. Y. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.01.033 · Cited by 622
A Global View of the Interplay between Non-Alcoholic Fatty Liver Disease and Diabetes
Stefan, N., & Cusi, K. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00003-1 · Cited by 593
Loomba, R., Abdelmalek, M. F., Armstrong, M. J., Jara, M., Kjær, M. S., Krarup, N., Lawitz, E., Ratziu, V., Sanyal, A. J., Schattenberg, J. M., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00068-7 · Cited by 533
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Ferguson, D., & Finck, B. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00507-z · Cited by 520
(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 545
Epidemiology and risk-stratification of NAFLD-associated HCC
Ioannou, G. N. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.012 · Cited by 361
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00754-7 · Cited by 354
Kanwal, F., Kramer, J. R., Li, L., Dai, J., Natarajan, Y., Yu, X., Asch, S. M., & El‐Serag, H. B. (2020) · Hepatology · doi:10.1002/hep.31014 · Cited by 319
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00366-5 · Cited by 316
The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease
Fujii, H., Kawada, N., & Japan Study Group of NAFLD (JSG-NAFLD) (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113863 · Cited by 308
NAFLD‐related hepatocellular carcinoma: The growing challenge
Shah, P. A., Patil, R., & Harrison, S. A. (2022) · Hepatology · doi:10.1002/hep.32542 · Cited by 270
Orci, L. A., Sanduzzi-Zamparelli, M., Caballol, B., Sapena, V., Colucci, N., Torres, F., Bruix, J., Reig, M., & Toso, C. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.05.002 · Cited by 218
Petta, S., Sebastiani, G., Viganò, M., Ampuero, J., Wai-Sun Wong, V., Boursier, J., Berzigotti, A., Bugianesi, E., Fracanzani, A. L., Cammà, C., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.06.045 · Cited by 197
Huang, D. Q., Noureddin, N., Ajmera, V. H., Amangurbanova, M., Bettencourt, R., Truong, E., Gidener, T., Siddiqi, H., Majzoub, A. M., Nayfeh, T., et al. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00157-7 · Cited by 198
Self-citationChanging etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide
Kim, D. Y. (2024) · Journal of Liver Cancer · doi:10.17998/jlc.2024.03.13 · Cited by 185
Metabolic liver disease in diabetes – From mechanisms to clinical trials
Dewidar, B., KAHL, S., Pafili, K., & Roden, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154299 · Cited by 167
Tan, D. J. H., Setiawan, V. W., Ng, C. H., Lim, W. H., Muthiah, M. D., Tan, E. X. X., Dan, Y. Y., Roberts, L. R., Loomba, R. S., & Huang, D. Q. (2022) · Hepatology · doi:10.1002/hep.32758 · Cited by 148
Self-citationNon‐alcoholic fatty liver disease and type 2 diabetes: An update
Lee, C., Lui, D. T. W., & Lam, K. S. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13756 · Cited by 139
The changing scenario of hepatocellular carcinoma in Italy: an update
Garuti, F., Neri, A., Avanzato, F., Gramenzi, A., Rampoldi, D., Rucci, P., Farinati, F., Giannini, E., Piscaglia, F., Rapaccini, G., et al. (2014) · Liver international (Print) · doi:10.1111/liv.14735 · Cited by 94
Kramer, J. R., Natarajan, Y., Dai, J., Yu, X., Li, L., El‐Serag, H. B., & Kanwal, F. (2021) · Hepatology · doi:10.1002/hep.32244 · Cited by 116
Natural history of NASH and HCC
Negro, F. (2020) · Liver international (Print) · doi:10.1111/liv.14362 · Cited by 88
Roeb, E., Canbay, A. E., Tacke, F., Bantel, H., Bojunga, J., de Laffolie, J., Demir, M., Denzer, U. W., Geier, A., Hofmann, W. P., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2283 · Cited by 108
Chrysavgis, L., Giannakodimos, I., Diamantopoulou, P., & Cholongitas, Ε. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i3.310 · Cited by 84
Kalai, F. Z., Boulaaba, M., Ferdousi, F., & Isoda, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020704 · Cited by 78
Shin, H. S., Jun, B. G., & Yi, S. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0383 · Cited by 72
HCC and Molecular Targeting Therapies: Back to the Future
Rinaldi, L., Vetrano, E., Rinaldi, B., Galiero, R., Caturano, A., Salvatore, T., & Sasso, F. C. (2021) · Biomedicines · doi:10.3390/biomedicines9101345 · Cited by 66
Mak, L., Hui, R. W., Lee, C., Mao, X., Cheung, K. S., Wong, D. K.-H., Lui, D. T. W., Fung, J., Yuen, M., & Seto, W. (2022) · Hepatology · doi:10.1002/hep.32716 · Cited by 64
Abdelhamid, A. M., Saber, S., Youssef, M. E., Gaafar, A. G. A., Eissa, H., Abdel-Dayem, M. A., Alqarni, M., Batiha, G. E., Obaidullah, A. J., Shahien, M. A., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112455 · Cited by 68
Talamantes, S., Lisjak, M., Gilglioni, E. H., Llamoza-Torres, C. J., Ramos‐Molina, B., & Gurzov, E. N. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100811 · Cited by 62
NAFLD-Associated HCC: Progress and Opportunities
Geh, D., Anstee, Q. M., & Reeves, H. L. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s272213 · Cited by 64
Motta, B. M., Masarone, M., Torre, P., & Persico, M. (2023) · Cancers · doi:10.3390/cancers15225458 · Cited by 61
Association between Liver Cirrhosis and Diabetes Mellitus: A Review on Hepatic Outcomes
Coman, L. I., Coman, O. A., Bădărău, I. A., Păunescu, H., & Ciocîrlan, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10020262 · Cited by 59
Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus
Mallet, V. O., Parlati, L., Martinino, A., Pereira, J. P. S., Jiménez, C. N., Sakka, M., Bouam, S., RETBI, A., Krasteva, D., Méritet, J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.030 · Cited by 57
Grgurević, I., Božin, T., Mikuš, M., Kukla, M., & O’Beirne, J. P. (2021) · Cancers · doi:10.3390/cancers13225844 · Cited by 58
Zhang, X., Wong, G. L., Yip, T. C., Cheung, J. T. K., Tse, Y., Hui, V. W., Lin, H., Lai, J. C., Chan, H. L., Kong, A. P. S., et al. (2022) · Hepatology · doi:10.1002/hep.32476 · Cited by 56
Xu, M., Tan, J., Dong, W., Zou, B., Teng, X., Zhu, L., Ge, C., Dai, X., Kuang, Q., Zhong, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28641-w · Cited by 53
Torres, M. C. P., Bodini, G., Furnari, M., Marabotto, E., Zentilin, P., Strazzabosco, M., & Giannini, E. G. (2020) · Cancers · doi:10.3390/cancers12061422 · Cited by 54
Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease
Hagström, H., Kechagias, S., & Ekstedt, M. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13343 · Cited by 52
Pinyopornpanish, K., Al-Yaman, W. A., Butler, R. S., Carey, W. W., McCullough, A. J., & Romero‐Marrero, C. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001347 · Cited by 51
Johnston, M. P., Patel, J. A., & Byrne, C. D. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200128094231 · Cited by 49
Performance Assessment of Classification Algorithms on Early Detection of Liver Syndrome
Naseem, R., Khan, B. A., Shah, M. A., Wakil, K., Khan, A., Alosaimi, W. A., Uddin, M. I., & Alouffi, B. (2020) · Journal of Healthcare Engineering · doi:10.1155/2020/6680002 · Cited by 47
Molecular links between non-alcoholic fatty liver disease and hepatocellular carcinoma
Raza, S., Rajak, S., Anjum, B., & Sinha, R. A. (2019) · Hepatoma Research · doi:10.20517/2394-5079.2019.014 · Cited by 47
Samy, A. M., Kandeil, M. A., Sabry, D., Abdel-Ghany, A. A., & Mahmoud, M. O. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30387 · Cited by 55
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients
Argenziano, M. E., Kim, M. N., Montori, M., Bucchianico, A. D., Balducci, D., Ahn, S. H., & Svegliati‐Baroni, G. (2024) · Hepatology International · doi:10.1007/s12072-024-10692-4 · Cited by 52
Lanjewar, M. G., Parab, J. S., Shaikh, A. Y., & Sequeira, M. D. (2022) · Cluster Computing · doi:10.1007/s10586-022-03752-7 · Cited by 42
Non-alcoholic fatty liver disease-related hepatocellular carcinoma
Daher, D., Dahan, K. S. E., & Singal, A. G. (2023) · Journal of Liver Cancer · doi:10.17998/jlc.2022.12.30 · Cited by 45
Hagström, H., Hegmar, H., & Moreno, C. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12524 · Cited by 40
Remodeling Lipids in the Transition from Chronic Liver Disease to Hepatocellular Carcinoma
Ismail, I. T., Elfert, A., Helal, M., Salama, I. A., El‐Said, H., & Fiehn, O. (2020) · Cancers · doi:10.3390/cancers13010088 · Cited by 40
Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges
Teng, Y., Xie, S., Guo, P.-P., Deng, Z., Zhang, Z., Gao, W., Zhang, W., & Zhong, J. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00586 · Cited by 41
Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
Sumida, Y., Yoneda, M., Seko, Y., Ishiba, H., Hara, T., Toyoda, H., Yasuda, S., Kumada, T., Hayashi, H., Kobayashi, T., et al. (2020) · Diagnostics · doi:10.3390/diagnostics10080579 · Cited by 32
Huang, P.-S., Wang, C., Yeh, C., & Lin, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205220 · Cited by 36
Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
Song, B. G., Choi, S. C., Goh, M. J., Kang, W., Sinn, D. H., Gwak, G., Paik, Y., Choi, M. S., Lee, J. H., & Paik, S. W. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100810 · Cited by 35
Ahmad, M. I., Khan, M. U., Kodali, S., Shetty, A., Bell, S. M., & Victor, D. W. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s344559 · Cited by 36
Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms
Lugari, S., Baldelli, E., & Lonardo, A. (2023) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.38 · Cited by 32
Zhang, X., Yip, T. C., Tse, Y., Hui, V. W., Li, G., Lin, H., Liang, L. Y., Lai, J. C., Chan, H. L.-Y., Chan, S. L., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000432 · Cited by 33
Harris, S., Poolman, T. M., Arvaniti, A., Cox, R., Gathercole, L., & Tomlinson, J. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00055.2020 · Cited by 35
The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective
Dokmak, A., Lizaola‐Mayo, B., & Trivedi, H. D. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.08.010 · Cited by 33
Teng, P., Huang, D. Q., Lin, T.-Y., Noureddin, M., & Yang, J. D. (2022) · Gut and Liver · doi:10.5009/gnl220357 · Cited by 34
Self-citationNAFLD in type 2 diabetes mellitus: Still many challenging questions
Cernea, S., & Raz, I. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3386 · Cited by 34
Authors, & Collaborators: (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2388 · Cited by 30
Shi, Y., Taherifard, E., Saeed, A., & Saeed, A. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46060356 · Cited by 33
Jaber, F. S., Cholankeril, G. T., & El‐Serag, H. B. (2024) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwae025 · Cited by 33
Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis
Tovo, C. V., de Mattos, Â. Z., Coral, G. P., SARTORI, G. D. P., Nogueira, L. V., Both, G. T., Villela‐Nogueira, C. A., & de Mattos, Â. A. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i2.343 · Cited by 35
NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay
Cernea, S. (2024) · Life · doi:10.3390/life14020272 · Cited by 30
El-Fattah, E. E. A., Saber, S., Youssef, M. E., Eissa, H., El-Ahwany, E. G., Amin, N. A., Alqarni, M., Batiha, G. E., Obaidullah, A. J., Kaddah, M. M. Y., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.720173 · Cited by 29
Antwi, S. O., Craver, E. C., Nartey, Y. A., Sartorius, K., & Patel, T. C. (2022) · Cancers · doi:10.3390/cancers14246234 · Cited by 30
Tong, Q., Qin, W. D., Li, Z., Liu, C., Wang, Z., Chu, Y., & Xu, X. (2023) · Cancer Medicine · doi:10.1002/cam4.5605 · Cited by 27
Kim, M. N., Han, K., Yoo, J., Hwang, S. G., Zhang, X., & Ahn, S. H. (2023) · International Journal of Cancer · doi:10.1002/ijc.34637 · Cited by 23
Tamaki, N., Wakabayashi, S., Kimura, T., Yasui, Y., Tsuchiya, K., Nakanishi, H., Huang, D. Q., Umemura, T., Kurosaki, M., & Izumi, N. (2024) · Hepatology Research · doi:10.1111/hepr.14025 · Cited by 22
Molecular Mechanisms Linking Nonalcoholic Steatohepatitis to Cancer
Wegermann, K., Hyun, J., & Diehl, A. (2021) · Clinical Liver Disease · doi:10.1002/cld.1006 · Cited by 18
Banerjee, A., Das, D., Mukherjee, S., & Maji, B. K. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112091 · Cited by 21
Lupșor‐Platon, M., Serban, T., Silion, A. I., Tirpe, A., & Florea, M. (2020) · Cancers · doi:10.3390/cancers12102778 · Cited by 20
Yuan, L., Hanlon, C. L., Terrault, N. A., Alqahtani, S. A., Tamim, H., Lai, M., & Saberi, B. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001591 · Cited by 20
Manka, P. P., Kaya, E., Canbay, A. E., & Syn, W. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07206-9 · Cited by 22
Sebastiani, G., Patel, K., Ratziu, V., Feld, J. J., Neuschwander‐Tetri, B. A., Pinzani, M., Petta, S., Berzigotti, A., Metrakos, P. P., Shoukry, N. H., et al. (2021) · Canadian Liver Journal · doi:10.3138/canlivj-2021-0030 · Cited by 20
GDI2 is a novel diagnostic and prognostic biomarker in hepatocellular carcinoma
Zhang, W., Liu, Z., Xia, S., Yao, L., Li, L., Gan, Z., Tang, H. J., Guo, Q., Yan, X., & Sun, Z. (2021) · Aging · doi:10.18632/aging.203748 · Cited by 19
Valibeygi, A., Davoodi, A., Dehghan, A., Vahid, F., Hébert, J. R., Farjam, M., & Homayounfar, R. (2023) · BMC Nutrition · doi:10.1186/s40795-023-00738-5 · Cited by 19
Identification of metabolic biomarkers associated with nonalcoholic fatty liver disease
Jiang, H., Hu, Y., Zhang, Z., Chen, X., & Gao, J. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01911-2 · Cited by 17
Xiao, S., Liu, Y., Fu, X., Chen, T., & Xie, W. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.06.031 · Cited by 17
Obesity Management of Liver Transplant Waitlist Candidates and Recipients
Brandman, D. (2020) · Clinics in Liver Disease · doi:10.1016/j.cld.2020.08.001 · Cited by 21
Chen, J., Song, S., Li, X., Bian, D., & Wu, X. (2021) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_260_21 · Cited by 19
From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players
Rodríguez‐Lara, A., Rueda‐Robles, A., Sáez‐Lara, M. J., Plaza‐Díaz, J., & Álvarez‐Mercado, A. I. (2023) · Pathogens · doi:10.3390/pathogens12070940 · Cited by 16
Billeter, A. T., Müller, P. C., Albrecht, T., Roessler, S. K., Löffler, M., Murtha-Lemekhova, A., Mehrabi, A., Müller-Stich, B. P., & Hoffmann, K. (2020) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-020-04628-0 · Cited by 16
Yan, L., Yao, S.-Y., Meng, G.-X., Liu, K., Li, H.-C., Ding, Z., Dong, Z., Hong, J., Chen, Z., & Li, T. (2021) · Hepatology International · doi:10.1007/s12072-021-10249-9 · Cited by 15
Lai, R., Chen, T., Hu, Y.-H., Wu, G. H., & Zheng, Q. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i23.3372 · Cited by 15
Peri-transplant management of nonalcoholic fatty liver disease in liver transplant candidates
Samji, N. S., Heda, R. P., & Satapathy, S. K. (2019) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.09.09 · Cited by 13
NAFLD and NAFLD-related HCC in Asia: Burden and Surveillance
Koh, J. H., Wang, M., Suzuki, H., Muthiah, M. D., Ng, C. H., & Huang, D. Q. (2023) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2023.06.013 · Cited by 15
Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
Song, B. G., Kim, A., Goh, M. J., Kang, W., Gwak, G., Paik, Y., Choi, M. S., Lee, J. H., & Sinn, D. H. (2024) · Liver Cancer · doi:10.1159/000538301 · Cited by 13
The role of bariatric surgery in the management of nonalcoholic steatohepatitis
Seymour, K. A., & Abdelmalek, M. F. (2021) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000721 · Cited by 13
Stratina, E., Stanciu, C., Năstasă, R., Zenovia, S., Stafie, R., Rotaru, A., Cuciureanu, T., Muzica, C. M., Sfarti, C. V., Gîrleanu, I., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14141475 · Cited by 12
Henry‐Blake, C., Balachandrakumar, V. K., Kassab, M., Devonport, J., Matthews, C., Fox, J. M., Baggus, E. M., Henney, A. E., Stern, N., Cuthbertson, D. J., et al. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16727 · Cited by 13
Lan, T., & Tacke, F. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156015 · Cited by 15
Prevention of hepatocellular carcinoma and surveillance of high risk patients
Kaya, E., Mazzolini, G. D., Yilmaz, Y. N., & Canbay, A. E. (2021) · Hepatology forum/Hepatology forum (Online) · doi:10.14744/hf.2021.2021.0033 · Cited by 14
Molecular Genealogy of Metabolic-associated Hepatocellular Carcinoma
Kodama, T., & Takehara, T. (2024) · Seminars in Liver Disease · doi:10.1055/a-2289-2298 · Cited by 15
Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin
Meroni, M., Longo, M., & Dongiovanni, P. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1411706 · Cited by 12
Alteration in immune function in patients with fatty liver disease
Gregory, S. N., Perati, S. R., & Brown, Z. J. (2022) · Hepatoma Research · doi:10.20517/2394-5079.2022.34 · Cited by 11
Costante, F., Airola, C., Santopaolo, F., Gasbarrini, A., Pompili, M., & Ponziani, F. R. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i9.1622 · Cited by 12
Metadata
- Authors
- Yang, J. D., Ahmed, F., Mara, K. C., Addissie, B. D., Allen, A. M., Gores, G. J., & Roberts, L. R.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Mayo Clinic (US)
- Geisinger Medical Center (US)
- Corresponding author
- Roberts, Lewis R.
- Venue
- Hepatology
- Published
- 2019-10-21
- Volume
- 71
- Issue
- 3
- Pages
- 907-916
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- PMC
- PMC6960360
- OpenAlex
- W2957370227
- Cited by
- 209
- References
- 41
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 40 · 2023: 31 · 2022: 38 · 2021: 29 · 2020: 30 · 2019: 4
- FWCI
- 19.21
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA186566, U54CA221205, CA210964, CA165076, R01CA165076, CA186566, CA 221205, P50CA210964)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- hepatocellular carcinoma, diabetes mellitus, nonalcoholic steatohepatitis, liver cirrhosis, non-alcoholic fatty liver disease, liver transplantation, serum albumin, age, HCC risk factors, liver disease progression, metabolic risk factors, body mass index, hyperlipidemia, hypertension, liver cancer incidence, Mayo Clinic Rochester, UNOS registry, external validation
- MeSH terms
- Adult, Age Factors, Aged, Female, Carcinoma, Hepatocellular, Humans, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Registries, Risk, Serum Albumin, Diabetes Complications, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
